奥拉西坦联合倍他司汀治疗卒中后眩晕对患者脑血流及血清AngⅡ、PDGF-BB水平的影响

doi:10.3969/j.issn.1671-7171.2024.11.011

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1272 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effects of combined treatment of Oxiracetam with Betahistine on cerebral blood flow and levels of angiotensin Ⅱ(Ang Ⅱ) and platelet-derived growth factor-BB (PDGF-BB) in patients with post-stroke dizziness.【Methods】Seventy-eight patients with post-stroke dizziness were randomly divided into the control group and the observation group, with 39 patients in each group. The control group was treated with betahistine mesylate tablets, while the observation group received additional treatment with xxiracetam in addition to betahistine. The cerebral blood flow, serum levels of Ang Ⅱ and PDGF-BB, dizziness severity (as assessed by the UCLA-DQ), and motion sensitivity (as assessed by the MSQ) were compared between the two groups before and after treatment.【Results】After treatment, both groups showed a significant increase in cerebral blood flow compared to before treatment (P<0.05), with the observation group exhibiting a greater increase than the control group (P<0.05). The levels of Ang Ⅱ and PDGF-BB significantly decreased after treatment in both groups (P<0.05), with lower levels observed in the observation group compared to the control group (P<0.05). The UCLA-DQ and MSQ scores significantly decreased after treatment in both groups (P<0.05), with the observation group showing lower scores than the control group (P<0.05).【Conclusion】The combination of oxiracetam and betahistine significantly improves cerebral blood flow in the affected regions of patients with post-stroke dizziness, reduces serum levels of Ang Ⅱ and PDGF-BB, alleviates dizziness symptoms, and enhances the quality of life. This treatment approach is worthy of clinical promotion and application.

Key words： Stroke/CO Vertigo/CO Betahistine/TU Cerebrovascular Circulation Angiotensin Ⅱ/BL

Received: 24 October 2023

PACS:

R743.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Chunli
	LI Pengju

Cite this article:

ZHENG Chunli,LI Pengju. Effects of Oxiracetam Combined with Betahistine on Cerebral Blood Flow and Serum Levels of Ang Ⅱ and PDGF-BB in Patients with Post-Stroke Dizziness[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(11): 1669-1671.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.11.011 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I11/1669

[1] 李刚,沈恒,汪纯,等. 奥拉西坦联合神经节苷脂注射液治疗对重症脑颅损伤患者血清NSE、S100蛋白水平的影响[J].医学临床研究,2019,36(2):338-340.
[2] 叶艳,李媚. 辨证分型联合奥拉西坦治疗眩晕临床观察[J].中国中医药现代远程教育,2021,19(16):138-139.
[3] 杜彦挺,杜光勇,贾喆,等. CT灌注成像评估颅脑损伤的程度及其对ICP探头置入术后脑血流动力学的预测价值[J].医学临床研究,2023,40(1):24-27.
[4] 段晓云,张辰慧,张宏,等. 中风醒脑液联合奥拉西坦治疗老年缺血性脑卒中的临床效果[J].中国老年学杂志,2022,42(11):2618-2621.
[5] 郭莹,杜静. 丁苯酞联合奥拉西坦对脑卒中后认知功能障碍患者炎性因子水平及认知功能的影响[J].反射疗法与康复医学,2022,3(23):147-150.
[6] 梁艳,姜鹏程,赵家龙,等. 血栓通注射液联合倍他司汀治疗对缺血性脑卒中患者血液流变学及血脂水平的影响[J].湖北中医药大学学报,2021,23(4):26-29.
[7] 孙丽燕,李景莉,李亚楠,等. 舒血宁注射液联合倍他司汀对椎-基底动脉供血不足性眩晕症患者椎-基底动脉血流速度和氧化应激的影响[J].现代生物医学进展,2022,22(14):2748-2752.
[8] 纪小美,任攀,刘进财,等. 穴位贴敷、耳穴贴压联合SRM-Ⅳ前庭功能诊疗系统治疗良性阵发性位置性眩晕复位后残余症状临床研究[J].河北中医,2023,45(3):446-449.
[9] 张晓阳. 倍他司汀联合丁苯酞对急性缺血性脑卒中的疗效[J].西藏医药,2021,42(5):82-83.
[10] 刘化飞,唐松林. 奥拉西坦联合倍他司汀对卒中后眩晕患者炎症因子及神经功能的影响[J].脑与神经疾病杂志,2023,31(1):48-52.
[11] 高博,吕涛,唐琴,等. 马来酸桂哌齐特联合甲磺酸倍他司汀对后循环缺血性眩晕患者的治疗效果[J].贵州医科大学学报,2022,47(1):119-124.
[12] 杜柏,胡元会,褚瑜光,等. 冠心病心衰气阴两虚型RAAS激活对心功能及脑血流的影响[J].中西医结合心脑血管病杂志,2016,14(16):1885-1887.
[13] 陆翠燕,潘伟锋,邵妤,等. 脑血康胶囊联合抗血小板治疗缺血性脑卒中的效果及对脑血流量的影响[J].实用临床医药杂志,2020,24(3):40-43.
[14] 郭相锐,高凯华,潘敏. 奥拉西坦对病毒性脑炎患儿脑电图特征和炎症因子水平的影响[J].当代医学,2022,28(9):10-12.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(9): 1424-1426.